Iovance Biotherapeutics (IOVA) stock

Cancer cell therapies , market cap $3.5B

Cancer cell therapies

Worth $3.5B

$8.08

-1.10%

As of Tuesday's close · Live for Pro members at the open

Why is IOVA down?

Down 45% from Oct 28 to Nov 10.

Iovance Biotherapeutics fell 45% from Oct 28 to Nov 10. 35 points of it came on Oct 29.

Sources: Price history, Nov 10, 2026

Tell me next time IOVA moves

Free account, no card. An optional alert when IOVA moves or its score changes.

Or see it live, free until Thursday morning. No account.

1 more reason, free with an account →2 more reasons why IOVA fell 45% since Oct 28, from its filings, with the other side, how the business stands, the timeline, and its peers, for Pro members.

Why IOVA still beats the market over a year

Up 245% over the year to Nov 9 while the S&P 500 rose 12%; down 45% since Oct 28.

4 reasons, from its filings, with the timeline and its peers, for Pro members.

Quality Score

Below Average

In its industry

#80of 281

Biotech

Checks firing

3of 14

Trending up

From 52-week high

-47.4%

under its best in a year

IOVA's Quality Score rose 1 point on Tue, Nov 10, to 5. Trading was quieter than usual (2 chart checks started).

Follow IOVA's trial news. Pro members can get an alert when Iovance Biotherapeutics files news, and see its trials, share raises, and its CEO's filings.

Get an alert when IOVA files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextNov 2026“biomarker-enriched cohort within the ongoing IOV-LUN-202 program, with enrollment to begin in November 2026…”Trial start · SEC filing · Oct 29

Key facts on IOVA

Key facts on IOVA
Holding it back	25.2% more shares than a year ago
Latest filing	8-K, Nov 5 Reported its quarterly results

1 more reason behind IOVA's 5, free with an account →5 more reasons behind IOVA's 5, for Pro members.

IOVA in the news

Fri Oct 30Iovance Reports Updated IOV-LUN-202 Results and Adds Precision TIL Strategy for Second-Line Metastatic Non-Small-Cell Lung Cancer (mNSCLC) Iovance Biotherapeutics' release, SEC filing 5:00 PM ET IOVA closed −11.3% that day.

Big story

Trial

Iovance Biotherapeutics to Host Webcast on Positive Phase 2 IOV-LUN-202 Results in Nonsquamous mNSCLC

IOVA closed −35.4% the next session (Oct 29) on 3.8x normal volume.

Reported by quiver quantitative · covered by 4 outlets

Get an alert on IOVA's next big story →

1 more big story on IOVA in the past 12 months, for Pro members.

IOVA catalysts

Coming up

After its last 4 reports it closed +12.4% on average, higher 2 of 4 times.

12 past catalysts since 2020, with sizes and sources, for Pro members.

What's next for IOVA, and how long its cash lasts

Next step the company has named

Nov 2026“biomarker-enriched cohort within the ongoing IOV-LUN-202 program, with enrollment to begin in November 2026 at the first of over 70 existing”Trial start · SEC filing · Oct 29

What it means: when a trial begins, or reaches the stage the company named.

Lead program: LUN-202
Another trial: Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.Phase 3 · Recruiting · 670 people · main data estimated Mar 1, 2028 · NCT05727904

7 more trials, 2 more milestones and 46 filings, for Pro members.

Cash runway

The company says its cash lasts into 2029 (8-K, Nov 5).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Jun 18, 2026)
At-the-market share sales program (S-3ASR, filed Jun 18, 2026)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

No open-market buys or sales by its officers or directors in their filings of the last year.

From Form 4: open-market buys and sales only.

Get an alert when Frederick Vogt buys or sells

For Pro members: every trade, and Frederick Vogt’s 20 filings and quotes.

Get an alert when IOVA files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why IOVA scores 5

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

Well below its recent run. IOVA scores 5 today, against a median of 9 over its last 20 recorded sessions.

+3Chart checks 3 of 14 firing right now, one point each
−2Dilution 25.2% more shares outstanding than a year agoNew shares over the year: -1 at 10% more, -2 at 25% more.

Long-term trend adds
Run-up adds
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.
Persistence adds

No effect today: Size, Profit, and News.

What every line is worth, and the reason behind it, on IOVA and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 10:45 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

How IOVA ranks in Biotech

IOVA is #80 of 281 by Quality Score.

How IOVA ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	INOInovio Pharmaceuticals		Open for its score
	IONSIonis Pharmaceuticals		Open for its score
	IPSCCentury Therapeutics		Open for its score
	IQVIQVIA		Open for its score
80	IOVAIovance Biotherapeutics	3/14	5

Share count against a year before: IOVA +25%, ADPT +5.2%, IBRX +12%, KYMR +15%.

When does IOVA report earnings, and what happens after?

Expected to report Tue Feb 23, before the open (in 105 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What IOVA reported on Nov 5, 2026

The quarter

Sales of $121.5M, 80% more than a year ago; a loss of $0.05 a share, from $0.25.

“with our highest gross margin ever, driven by continued U.S. Amtagvi demand,” said Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

Where the quarter's sales came from
Line	Q3 2026	Q2 2026	Q3 2025
By region
United Statesup 81%	$120M99%	$99M99%	$66.4M98%

Each quarter's sales and their share of its total. Figures as filed (SEC filing, Nov 5)

1 more line, for Pro members.

The outlook

The outlook the company gave, by period
Measure	Figure
Full year 2026
Total revenue	$410M to $420Mkept

Figures as filed (SEC filing, Nov 5)

In the company's words

“Improvements in gross margin are expected to continue, excluding occasional one-time items.”

From its results filing (SEC filing · Nov 5)

The numbers

Market value: $3.5B; today
Sales: $379M; up 51.3% on the year
Free cash flow: -$216M; last 12 months

2 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on IOVA: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 4

+30.8%-13.2%+43.1%-11.0%

Feb 24May 7Aug 6Nov 5

Reported	When	Gap	Reaction	5 days
Nov 5, 2026Before open	Before open	-3.5%	-11.0%	not yet
Aug 6, 2026Before open	Before open	+37.1%	+43.1%	+55.3%
May 7, 2026Before open	Before open	-14.2%	-13.2%	-10.5%
Feb 24, 2026Before open	Before open	+14.0%	+30.8%	+31.1%

IOVA closed higher after 2 of its last 4 reports.

IOVA sales and profit by year

Sales and profit by year

Sales grew every year from 2023 to 2025, to $264M. It lost money in each of the three years.

IOVA has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on IOVA, and all 14 on every stock.Get in free →

IOVA RSI today: 33.4, below its 50-day, above its 200-day

Not scored

RSI 33.4, MACD below signal, below its 50-day, above its 200-day. Not scored.13 readings

The deep dive on IOVA

What it does and how it makes money2 findingsAn operating loss of $403M in fiscal 2025, on $264M of sales.Annual report, filed Feb 24, 2026
Where it stands1 findingFor Pro members1 finding on where IOVA stands: its cash, debt, and share count, for Pro members
What changed in its filings4 findings"Following oral argument on December 3, 2025, the court denied the Solomon Plaintiffs’ motion for leave to amend and granted the Company’s motion for summary judgment." (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 5, 2026A new heading in its "Risk Factors" this year: "We may be unable to realize the expected benefits from restructuring activities, including workforce reductions, and our business might be adversely affected." (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 24, 2026, against the one of Feb 27, 2025
Who holds and trades it1 findingFor Pro members1 finding on who holds and trades IOVA, for Pro members
Against its closest peers4 peersShare count against a year before: IOVA +25%, ADPT +5.2%, IBRX +12%, KYMR +15%.

5 more findings on IOVA, each with its source, for Pro members.

IOVA share count over time

Shares: 25.2% more than a year ago (to Sep 30).

Shares of IOVA outstanding, as filed
Shares outstanding	As of
462.7M	Oct 27, 2026
453M	Jul 29, 2026
446.5M	Apr 15, 2026
412M	Feb 13, 2026

Offerings, shelves, and splits of IOVA, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Jun 18, 2026
Set up an at-the-market program for up to $350M of shares, about 10% of its market value	Aug 22, 2025
Priced a sale of shares	Feb 21, 2024

IOVA's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Frederick G. VogtInterim CEO & General Counsel · no trades on file
Corleen M. RocheChief Financial Officer · no trades on file
Daniel Gordon KirbyChief Commercial Officer · no trades on file
Finckenstein Friedrich GrafChief Medical Officer · no trades on file
Igor BilinskyChief Operating Officer · no trades on file
Raj K. PuriChief Regulatory Officer · no trades on file

See insider trades by person

Which ETFs hold IOVA?

In ETFs: IOVA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About Iovance Biotherapeutics

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

975 employeesSan Carlos, CAiovance.com

What Iovance Biotherapeutics says it competes with

“Many of these companies and our other current and potential competitors have substantially greater research and development capabilities and financial, scientific, regulatory, manufacturing, marketing, sales, human resources, and experience than we do.”

From its annual report, SEC filing · Feb 24, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on IOVA and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn IOVA's score around: 7 things
9 more filings explained, a plain line each
Real-⁠time prices, no delay

See IOVA's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: IOVA's Quality Score is 5 (Below Average), #80 of 281 in Biotech.

What does IOVA's Quality Score say?

IOVA scores 5 today, which Breakaway calls Below Average. It is #80 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Down 45% from Oct 28 to Nov 10. Shares: 25.2% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is IOVA's Quality Score?

IOVA scores 5 today, which Breakaway calls Below Average (0 to 5). That is #80 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind IOVA's 5.

When does IOVA report earnings?

Expected to report Tue Feb 23, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. IOVA closed higher after 2 of its last 4 reports. Past behavior, not a forecast.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.